Objective:To systematically evaluate the efficacy and safety of Suhuang Zhike Capsules in treating chronic obstructive pulmonary disease(COPD)and to analyze the multi-target and multi-pathway intervention mechanisms of Suhuang Zhike Capsules in treating COPD using network pharmacology and molecular docking technology.Methods:Based on meta-analysis,the clinical total effective rate and adverse reactions of Suhuang Zhike Capsules in treating COPD were evaluated.The effective components and action targets of Suhuang Zhike Capsules were preliminarily predicted through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and GeneCards database,respectively,and the target information was standardized.COPD targets were selected through various databases.Suhuang Zhike Capsules targets and COPD targets were integrated to obtain the key targets for treating COPD.A protein-protein interaction(PPI)network was constructed to identify core targets,and GO and KEGG enrichment analyses were performed for intersection targets.The key active components of Suhuang Zhike capsule and core targets of COPD were verified by molecular docking.Results:Results of meta-analysis showed that compared with conventional treatment,combined with Suhuang Zhike Capsules significantly improved the clinical total effective rate(OR=4.26,95%CI:3.20-5.68,P＜0.01).There was no statistically significant difference between the two groups in the incidence of adverse reactions(P＞0.05).The network pharmacology results showed 90 active compounds,141 COPD-related targets,and 103 related pathways.Molecular docking results indicated that the core components of Suhuang Zhike Capsules,such as luteolin,quercetin,and kaempferol,were successfully docked with core targets of COPD,including epidermal growth factor receptor(EGFR),serine/threonine kinase 1(AKT1),and matrix metalloproteinase 9(MMP9),with all binding energies＜-5 kcal/mol,indicating good binding activity.Conclusions:Conventional treatment combined with Suhuang Zhike Capsules can improve clinical efficacy and has good safety in treating COPD.Suhuang Zhike Capsules may be involved in the treatment of COPD through multiple-target and multiple-pathway.This study provides bioinformatics support and safety evaluation for the clinical application of Suhuang Zhike Capsules in treating COPD and provides new insights for further research.